Structural Heart Devices Market Report Scope and Overview:

The Structural Heart Devices Market was valued at USD 13.10 Billion in 2025 and is projected to reach USD 32.15 Billion by 2035, registering a CAGR of 9.4% from 2026 to 2035. The market continues expanding steadily.

The Structural Heart Devices Market is steadily transforming valvular and structural cardiac disease treatment by shifting open-heart procedures toward minimally invasive transcatheter alternatives that reduce recovery time and expand eligibility to higher-risk patients. The market is characterized by rising adoption of transcatheter aortic valve replacement across all surgical risk categories, growing integration of transseptal mitral and tricuspid valve therapies into structural heart programs, and expanding use of left atrial appendage closure as an alternative to long-term anticoagulation. Significant growth is being witnessed in transcatheter tricuspid repair and next-generation occluder platforms, considering that hospitals, cath labs and device manufacturers continue investing in infrastructure that improves patient outcomes and reduces procedural risk.

Edwards Lifesciences received FDA approval for its SAPIEN M3 mitral valve replacement system in 2025, the first transseptal transcatheter therapy approved for mitral regurgitation, reflecting the industry's broader shift toward transcatheter alternatives for complex structural valve disease.

Structural Heart Devices Market Trends

• Rising adoption of transcatheter aortic valve replacement across all surgical risk categories continues expanding the eligible patient population.

• Growing integration of transseptal mitral and tricuspid valve therapies continues broadening treatment options for structural valve disease.

• Expanding use of left atrial appendage closure continues offering an alternative to long-term anticoagulation therapy.

• Increasing adoption of transcatheter tricuspid repair devices continues addressing a historically undertreated patient population.

• Rising strategic competition among device manufacturers continues reshaping the competitive structural heart device vendor landscape.

U.S. Structural Heart Devices Market Outlook

The U.S. Structural Heart Devices Market was valued at approximately USD 5.01 Billion in 2025 and is projected to reach approximately USD 11.97 Billion by 2035, registering a CAGR of approximately 9.1% from 2026 to 2035.

Demand across the United States continued to be shaped by high structural heart disease prevalence among an aging population, growing surgeon and patient preference for minimally invasive transcatheter procedures over open-heart surgery, and expanding Medicare coverage supporting broader TAVR patient eligibility. Rising deployment of advanced valve and occluder platforms by leading hospital systems and cardiac catheterization labs continued reinforcing the country's position as the largest and most technologically advanced structural heart devices market. Growing adoption of transcatheter tricuspid repair and replacement therapies added further layers of sustained domestic demand, with expanding structural heart programs increasingly relying on multidisciplinary heart teams to guide treatment selection.

Boston Scientific continued expanding adoption of its WATCHMAN FLX Pro left atrial appendage closure device in 2025, securing an FDA label expansion covering post-ablation atrial fibrillation patients across American hospital and cath lab deployments.

Structural Heart Devices Market Segment Analysis

• By Product, Heart valve devices segment dominated the Structural Heart Devices Market in 2025 with 64% share; Occluders and delivery systems segment is the fastest growing segment with a CAGR of approximately 11.8%.

• By Procedure, Replacement procedures segment dominated the Structural Heart Devices Market in 2025 with 68% share; Repair procedures segment is the fastest growing segment with a CAGR of approximately 12.4%.

• By End Use, Hospitals segment dominated the Structural Heart Devices Market in 2025 with 59% share; Cardiac catheterization labs segment is the fastest growing segment with a CAGR of approximately 11.6%.

By Product: Heart Valve Devices Lead, Occluders and Delivery Systems Grow Fastest

The Heart valve devices segment dominated the Structural Heart Devices Market in 2025, driven by the sheer clinical volume of aortic, mitral, and tricuspid valve disease requiring surgical or transcatheter replacement across aging populations worldwide. Continued expansion of transcatheter heart valve platforms across hospitals sustained steady valve revenue as programs upgraded from surgical-only toward transcatheter-first treatment pathways. Growing preference for transcatheter aortic and mitral valve platforms that reduce recovery time reinforced this segment's position as the largest contributor to total market spending throughout the base year. Continued expansion of durable tissue valve technology further reinforced premium valve adoption among younger, lower-risk patients.

The Occluders and delivery systems segment is the fastest growing in the Structural Heart Devices Market owing to rising demand for left atrial appendage closure as a stroke prevention alternative to long-term oral anticoagulation in atrial fibrillation patients. Growing adoption of next-generation occluder platforms featuring improved anatomical conformability continues expanding recurring device demand beyond conventional valve replacement. Rising vendor investment in expanded labeling covering post-ablation and broader anticoagulation-ineligible populations is accelerating this segment's growth trajectory across hospital and cath lab settings worldwide. Growing physician confidence in occluder conformability continues expanding adoption among complex anatomies.

By Procedure: Replacement Procedures Dominate, Repair Procedures Grow Fastest

The Replacement procedures segment dominated the Structural Heart Devices Market because transcatheter and surgical aortic valve replacement together address the highest-volume structural heart condition, severe aortic stenosis, across nearly all patient risk categories worldwide. Broad clinical evidence supporting TAVR's expansion from extreme-risk to low-risk and now asymptomatic patients sustained replacement procedures' dominant position throughout the base year. Continued refinement of valve platforms compatible with diverse anatomies reinforced this procedure category's leading contribution to total market revenue. Continued expansion of redo-TAVR capability for prior valves reinforced this category's broad installed base.

The Repair procedures segment is the fastest growing due to rising demand for left atrial appendage closure, transcatheter mitral and tricuspid valve repair, and valvuloplasty among patients historically underserved by replacement therapy alone. Growing clinical evidence supporting transcatheter edge-to-edge repair's role in treating tricuspid regurgitation continues expanding adoption among previously untreated patient populations. Rising vendor investment in next-generation repair platforms is accelerating this procedure category's transition from niche use toward broader structural heart program adoption. Growing clinical training, programs focused on transseptal repair techniques continue expanding physician adoption confidence.

By End Use: Hospitals Dominate, Cardiac Catheterization Labs Grow Fastest

The Hospitals segment dominated the Structural Heart Devices Market because hospitals remain the primary site of complex structural heart procedures requiring full surgical and interventional infrastructure support. Large hospital systems continue operating the highest procedure volumes globally, sustaining consistent capital equipment, valve, and occluder consumable demand. Continued investment in dedicated structural heart programs within hospital systems reinforced this segment's dominant contribution to total market revenue throughout the base year. Continued expansion of multidisciplinary heart team programs within hospital systems further reinforced hospital-based device technology leadership.

The Cardiac catheterization labs segment is the fastest growing as transcatheter structural heart procedures continue shifting toward dedicated cath lab settings offering efficient, image-guided procedural workflows outside traditional surgical suites. Growing numbers of transcatheter aortic valve and left atrial appendage closure procedures increasingly rely on advanced imaging-equipped cath labs suited to high-throughput interventional workflows. Expanding investment in cath lab infrastructure continues attracting a broadening base of facilities toward advanced structural heart device adoption. Growing insurer support for outpatient structural heart procedure reimbursement continues accelerating cath lab device adoption nationwide.

Regional Analysis

North America Structural Heart Devices Market Insights

North America dominated the Structural Heart Devices Market with the largest revenue share of approximately 44.0% in 2025. Robust hospital and cath lab infrastructure, significant device manufacturer presence, and high structural heart disease prevalence continued reinforcing this dominant regional position. A deep concentration of leading device vendors, structural heart training centers, and integrated health systems headquartered across the region gave regional hospitals early access to next-generation transcatheter valve and occluder platforms well ahead of most other regions. Growing collaboration between academic medical centers and device manufacturers further reinforced this region's technology leadership position.

The United States accounted for the substantial majority of regional revenue, anchored by high structural heart disease prevalence among an aging population, growing preference for minimally invasive transcatheter procedures, and expanding Medicare coverage supporting broader patient eligibility. Canada added further demand through its own growing structural heart program investment, and that combined strength kept the region the largest addressable market for structural heart device vendors through the forecast period. Continued expansion of transcatheter tricuspid repair programs across major metropolitan hospital systems reinforced sustained device demand.

Europe Structural Heart Devices Market Insights

Europe held a meaningful share of global revenue, supported by strong national health system investment, growing adoption of transcatheter valve therapies, and continued collaborative research programs between hospitals and device manufacturers across the region's major economies. Regulatory harmonization under the EU Medical Device Regulation and continued expansion of national structural heart program funding continued lowering historically significant barriers to advanced device technology adoption across the continent. Continued expansion of national transcatheter therapy reimbursement pilot programs further reinforced regional device adoption across public hospital networks.

Germany continued to lead demand at roughly 20.40% of European revenue, supported by its substantial hospital infrastructure and high structural heart procedure volumes among the region's largest economies. The UK and France contributed substantial additional demand through their own well-funded national health systems and growing transcatheter therapy adoption programs, and continued European investment in cath lab infrastructure should keep regional demand for structural heart devices climbing through the forecast period. Additional demand from Italy and Spain reinforced broader Southern European market strength throughout the forecast period.

Asia Pacific Structural Heart Devices Market Insights

Asia Pacific is advancing at the fastest pace, growing at a CAGR of approximately 11.9% from 2026 to 2035. This growth is driven by expanding hospital infrastructure and rising structural heart disease prevalence in China, Japan, and India, rising government initiatives to strengthen domestic cardiac interventional capacity, with expanding cath lab infrastructure continuing to broaden the region's addressable installation base well beyond its traditional smaller footprint. Rising medical tourism volumes across the region further reinforced demand for advanced structural heart device infrastructure.

China held a substantial share of regional revenue, supported by product launches from major market players and rapid expansion of domestic hospital structural heart infrastructure. India and Japan contributed meaningful additional demand, with India's growing structural heart procedure volumes and Japan's advanced device manufacturing base both reinforcing the region's position as the fastest-growing market tracked in this report. South Korea and Australia contributed smaller but steadily growing regional demand throughout the period.

MEA and Latin America Structural Heart Devices Market Insights

The Middle East and Africa and Latin America both showed steady growth, driven by expanding hospital infrastructure, rising government investment in healthcare modernization, and growing demand for locally accessible structural heart treatment capability across both areas. As these markets continued building out modern cath lab infrastructure, structural heart device technology proved a genuinely efficient way to expand advanced interventional cardiology capability without the decades-long buildout wealthier nations required. Growing medical tourism investment across both regions further reinforced demand for advanced cardiac interventional infrastructure.

Saudi Arabia led Middle East and Africa demand, supported by the country's substantial healthcare infrastructure investment under its national hospital expansion programs. The UAE contributed further demand through its own expanding private hospital network. In Latin America, Brazil accounted for the largest share of regional revenue, with growing hospital construction and cardiac interventional investment continuing to anchor regional demand for structural heart devices. Mexico contributed additional demand through expanding private hospital cardiac interventional investment.

Market Dynamics

Growth Drivers: Rising Structural Heart Disease Prevalence and Growing Transcatheter Adoption

The industry is driven by rising global structural heart disease prevalence among aging populations, growing patient and surgeon preference for minimally invasive transcatheter procedures, increasing regulatory momentum expanding TAVR and repair device eligibility, and expanding cath lab infrastructure investment. As hospitals continue prioritizing procedural safety and patient recovery, the need for advanced structural heart device technology continues driving adoption across both replacement and repair procedure settings worldwide. Growing hospital investment in dedicated structural heart programs further reinforces this sustained industry-wide demand driver.

Rising clinical evidence supporting transcatheter therapies over conventional open-heart surgery continues reinforcing this driver, as more hospitals adopt platforms capable of treating aortic, mitral, and tricuspid valve disease with reduced procedural risk. Growing integration of advanced imaging directly into structural heart procedural workflows continues improving physician confidence, and that combination of transcatheter innovation and imaging integration is exactly what keeps demand climbing at such a steady, sustained pace. Expanding physician training partnerships between device manufacturers and academic institutions is further widening this addressable base.

Restraints: High Device Costs and Reimbursement Constraints

The substantial capital cost of advanced transcatheter valve and occluder systems continues posing a genuine restraint on faster market-wide expansion, particularly across smaller hospitals and cath labs in developing regions without the capital budgets that large hospital networks can commit. That cost profile has kept large-scale, structural heart program deployment concentrated among a comparatively small number of well-resourced health systems. Extended capital approval cycles further discourage rapid device adoption among smaller healthcare facilities.

Inconsistent insurance reimbursement and national coverage determination limitations continue posing a further restraint, as many health systems restrict transcatheter procedure coverage to specific risk categories pending broader regulatory and payer reassessment. That reimbursement gap keeps some patients reliant on conventional surgical treatment rather than accessing advanced transcatheter therapy of their own choosing. Limited standardization of national coverage policies continues prolonging this regional adoption gap.

Opportunities: Repair Procedure Expansion and Emerging Market Cath Lab Infrastructure

Rising investment in transcatheter mitral and tricuspid repair platforms represents a significant opportunity, as structural heart physicians increasingly seek technology capable of treating previously untreated valve disease populations. Vendors positioned early in transseptal delivery and repair device innovation stand to capture meaningful share as this capability continues expanding from aortic-only programs into comprehensive multi-valve structural heart offerings. Expanding academic partnerships focused on next-generation delivery system engineering continue widening this addressable opportunity.

Closing cath lab infrastructure gaps across emerging healthcare markets offers a second substantial opportunity, as rising government healthcare spending and hospital construction initiatives continue creating fresh demand for accessible structural heart device infrastructure. Vendors with proven, cost-effective device platforms stand to capture meaningful share as developing economies increasingly expand cath lab capacity to support rising structural heart procedure volumes at scale. Continued government-backed hospital accreditation programs across Southeast Asia are further accelerating local technology adoption.

Recent Developments:

• 2025: Medtronic received FDA approval for an expanded Redo-TAVR indication for its Evolut TAVR systems, enabling valve-in-valve implantation for patients with a failed prior transcatheter valve.

• 2025: Anteris Technologies reported favorable one-year clinical outcomes for its DurAVR transcatheter heart valve and enrolled first patients in its PARADIGM pivotal trial against approved TAVR devices.

• 2025: JenaValve Technology completed its pivotal trial supporting FDA premarket approval of the Trilogy transcatheter heart valve, the first device approved for symptomatic, severe aortic regurgitation patients.

Structural Heart Devices Market key players are:

• Edwards Lifesciences Corporation

• Medtronic plc

• Abbott Laboratories

• Boston Scientific Corporation

• Johnson & Johnson MedTech

• LivaNova PLC

• Artivion, Inc.

• Meril Life Sciences Pvt. Ltd.

• Venus Medtech (Hangzhou) Inc.

• Peijia Medical Limited

• JenaValve Technology, Inc.

• Anteris Technologies Ltd.

• Occlutech Holding AG

• W. L. Gore & Associates, Inc.

• MicroPort CardioFlow Medtech Corporation

• 4C Medical Technologies, Inc.

• HighLife SAS

• Cardiovalve Ltd.

• Foldax, Inc.

• CroiValve Ltd.

Structural Heart Devices Market Report Scope: